Finasteride modifies the relation between serum C-peptide and prostate cancer risk: Results from the prostate cancer prevention trial

Cancer Prevention Research

Volumn 3, Issue 3, 2010, Pages 279-289

  Neuhouser, Marian L ^a   Till, Cathee ^a   Kristal, Alan ^a,b   Goodman, Phyllis ^a   Hoque, Ashraful ^c   Platz, Elizabeth A ^d   Hsing, Ann W ^e   Albanes, Demetrius ^e   Parnes, Howard L ^e   Pollak, Michael ^f  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; FINASTERIDE; LEPTIN; PLACEBO;

ADULT; ARTICLE; CANCER GRADING; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME; TUMOR BIOPSY;

C-PEPTIDE; CASE-CONTROL STUDIES; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FINASTERIDE; HUMANS; INSULIN RESISTANCE; LEPTIN; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 77949684390     PISSN: 19406207     EISSN: None     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-09-0188     Document Type: Article

References (75)

1. Hsu I, Kim S, Kabir M, Bergman R. Metabolic syndrome, hyperinsulinemia and cancer. Am J Clin Nutr 2007;86:867-71S.
2. Zhou J, Blackburn GL, Walker A. Symposium introduction: metabolic syndrome and the onset of cancer. Am J Clin Nutr 2007;86:817-9S.
3. Laukkanen JA, Laaksonen DE, Niskanen L, et al. Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol Biomarkers Prev 2004;13:1646-60.
4. Costello LC, Franklin RB. The intermediary metabolism of the prostate: a key to understanding the pathogenesis and progression of prostate malignancy. Oncology 2000;59:269-82.
5. Hsing AW, Gao Y, Chua S, Deng J, Stanczyk FZ. Insulin resistance and prostate cancer risk. J Natl Cancer Inst 2003;95:67-71.
6. Hsing AW, Chua S, T GY, et al. Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J Natl Cancer Inst 2001;93:783-9.
7. Ma J, Li H, Giovannucci E, et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet 2008;9:1039-47.
8. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000;106:473-81.
9. White MF, Kahn CR. The insulin signaling system. J Biol Chem 1994;269:1-4.
10. Venkateswaran V, Haddad AQ, Fleshner NE, et al. Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. J Natl Cancer Inst 2007;99:1793-800.
11. Chan JM, Stampfer MJ, Ma J, et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002;94:1099-109.
12. Gottlob K, Majewski N, Kennedy S, et al. Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Gene Dev 2001;15:1406-18.
13. Calle R, Rodriguez C, Walker-Thurmond K, Thun M. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U S. adults. N Engl J Med 2003;348:1625-38.
14. Gong Z, Neuhouser ML, Goodman PJ, et al. Obesity, diabetes, and risk of prostate cancer: results from the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev 2006;15:1977-83.
15. Kaaks R, Lukanova A. Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc Nutr Soc 2001;60:91-106.
16. Cox ME, Gleave ME, Zakikhani M, et al. Insulin receptor expression by human prostate cancers. Prostate 2009;68:1-8.
17. Kitazawa M, Shibata Y, Hashimoto S, Ohizumi Y, Yamakuni T. Proinsulin C-peptide stimulates a PKC/IκB/NF-κB signaling pathway to activate COX-2 gene transcription in Swiss 3T3 fibroblasts. J Biochem 2006;139:1083-8.
18. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors. JAMA 2003;289:76-9.
19. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab 2004;89:2583-9.
20. Kelley D, Goodpaster B. Effects of physical activity on insulin action and glucose tolerance in obesity. Med Sci Sports Exer 1999;31:S619-23.
21. Barnard ND, Scialli AR, Turner-McGrievy G, Lanou AJ, Glass J. The effects of a low-fat, plant-based dietary intervention on body weight, metabolism, and insulin activity. Am J Med 2005;118:991-7.
22. Wolever TMS, Mehleng C. Long-term effect of varying the sources or amount of dietary carbohydrate on postprandial plasma glucose, insulin, triacylglycerol, and free fatty acid concentrations in subjects with impaired glucose tolerance. Am J Clin Nutr 2003;77:612-21.
23. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-28.
24. Wei EK, Ma J, Pollak MN, et al. C-peptide, insulin-like growth factor binding protein-1, glycosylated hemoglobin, and the risk of distal colorectal adenoma in women. Cancer Epidemiol Biomarkers Prev 2006;15:750-5.
25. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr 2001;131:3109-20s.
26. Okumura M, Yamamoto M, Sakuma H, et al. Leptin and high glucose stimulate cell proliferation in MCF-7 human breast cancer cells: reciprocal involvement of PKC-α and PPAR expression. Biochem Biophys Acta 2002;1592:107-16.
27. Kabat GC, Kim M, Chlebowski RT, et al. A longitudinal study of the metabolic syndrome and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 2009;18:2046-53.
28. Stocks T, Lukanova A, Rinaldi S, et al. Insulin resistance is inversely related to prostate cancer: a prospective study in Northern Sweden. Int J Cancer 2007;120:2678-86.
29. Albanes D, Weinstein SJ, Wright ME, et al. Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer. J Natl Cancer Inst 2009;101:1272-9.
30. Borugian MJ, Spinelli JJ, Sun Z, et al. Prediagnostic C-peptide and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2007;16:2164-5.
31. Baratta M. Leptin - from a signal of adiposity to a hormonal mediator in peripheral tissues. Med Sci Monitor 2002;8:RA282-92.
32. Harris R. Leptin - much more than a satiety signal. Ann Rev Nutr 2000;20:45-75.
33. 2-terminal kinase. J Biol Chem 2003;278:42660-7.
34. Saglam K, Aydur E, Yilmaz M, Goktas S. Leptin influences cellular differentiation and progression in prostate cancer. J Urol 2003;169:1308-11.
35. Frankenberry KA, Somasundar P, McFadden DW, Vona-Davis LC. Leptin induces cell migration and the expression of growth factors in human prostate cancer cells. Am J Surg 2004;188:560-5.
36. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24.
37. Thompson IM, Chi C, Ankerst DP, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 2006;98:1128-33.
38. Lucia MS, Darke AK, Goodman PJ, et al. Pathologic characteristics of cancers detected in the Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention. Cancer Prevention 2008:1-7.
39. Lucia MS, Epstein JI, Goodman PJ, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst Monogr 2007;99:1375-83.
40. Kristal AR, King IB, Albanes D, et al. Centralized blood processing for the selenium and vitamin E cancer prevention trial: effects of delayed processing on carotenoids, tocopherols, insulin-like growth factor-I, insulin-like growth factor binding protein 3, steroid hormones, and lymphocyte viability. Cancer Epidemiol Biomarkers Prev 2005;14:727-30.
41. Neuhouser ML, Kristal AR, McLerran D, Patterson RE, Atkinson J. Validity of short food frequency questionnaires used in cancer chemoprevention trials: results from the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev 1999;8:721-5.
42. Neuhouser ML, Kristal AR, Patterson RE, Goodman PJ, Thompson IM. Dietary supplement use in the Prostate Cancer Prevention Trial: implications for prevention trials. Nutr Cancer 2001;39:12-8.
43. Kristal AR, Arnold KB, Schenk JM, et al. Dietary patterns, supplement use and risk of symptomatic benign prostatic hyperplasia (BPH): results from the Prostate Cancer Prevention Trial. Am J Epidemiol 2008;167:925-34.
44. Lohman T, Roche A, Martorell M. Anthropometric standardization reference manual. Champaign (IL): Human Kinetics Books; 1988.
45. Expert Panel on the Identification Evaluation, and Treatment of Overweight in Adults. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Am J Clin Nutr 1998;68:899-917.
46. Satia-Abouta J, Patterson RE, Schiller RN, Kristal AR. Energy from fat is associated with obesity in U S. men: results from the Prostate Cancer Prevention Trial. Prev Med 2002;34:493-501.
47. Brawley OW, Knopf K, Thompson I. The epidemiology of prostate cancer. Part II. The risk factors. Sem Urol Oncol 1998;16:193-201.
48. Gong Z, Agalliu I, Lin DW, Stanford JL, Kristal AR. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. Cancer 2007;109:1192-202.
49. Rodriguez C, Freedland SJ, Deka A, et al. Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 2007;16:63-9.
50. Makridakis N, Reichardt JKV. Pharmacogenetic analysis of human steroid 5a reductase type II: comparison of finasteride and dutasteride. J Mol Endocrinol 2005;34:617-23.
51. Song Y, Tangen C, Goodman PJ, et al. Finasteride, prostate cancer, and weight gain: evidence for genetic or environmental factors that affect cancer outcomes during finasteride treatment. Prostate 2008;68:281-6.
52. Roehrborn CG, Lee M, Meehan A, Waldstreicher J. Effects of finasteride on serum testosterone and body mass index in men with benign prostatic hyperplasia. Urology 2003;62:894-9.
53. Kooperberg C, Tuczinski I, LeBlanc ML, Hsu L. Sequence analysis using logic regression. Genet Epidemiol 2001;21:S626-31.
54. Hung RJ, Brennan P, Malaveille C, et al. Using hierarchical modeling in genetic association studies with multiple markers: application to a case-control study of bladder cancer. Cancer Epidemiol Biomarkers Prev 2004;13:1013-21.
55. Chatterjee N, Kalaylioglu Z, Moslehi R, Peters U, Wacholder S. Powerful multilocus tests of genetic association in the presence of genegene and gene-environment interactions. Am J Hum Genet 2006;79:1002-16.
56. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Diabetes mellitus and risk of prostate cancer (US). Cancer Causes Control 1998;9:3-9.
57. Waters KM, Henderson BE, Stram DO, et al. Association of diabetes with prostate cancer risk in the multiethnic cohort. Am J Epidemiol 2009;169:937-45.
58. Cowie CC, Rust KF, Byrd-Holt DD, et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002. Diabetes Care 2006;29:1263-8.
59. Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men. Diabetes Care 2000;23:490-4.
60. Li C, Ford ES, McGuire LC, et al. Trends in hyperinsulinemia among nondiabetic adults in the US. Diabetes Care 2006;29:2396-402.
61. Holman RR, Paul SK, Bethel A, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetics. N Engl J Med 2008;359:1577-89.
62. Zakikhani M, Dowling RJ, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006;66:10269-73.
63. Zakikhani M, Dowling RJ, Sonenberg N, Pollak MN. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prevention Research 2008;1:369-75.
64. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008;8:915-28.
65. Algire C, Zakikhani M, Blouin MJ, Shuai JH, Pollak M. Metformin attenuates the stimulatory effect of high-energy diet on in vivo LLC1 carcinoma growth. Endocr Relat Cancer 2008;15:833-9.
66. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007;67:10804-12.
67. Hoque A, Chen H, Xu X-C. Statin induces apoptosis and cell growth arrest in prostate cancer cells. Cancer Epidemiol Biomarkers Prev 2008;17:88-94.
68. Jacobs EJ, Rodriguez C, Bain EB, et al. Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U S. cohort. Cancer Epidemiol Biomarkers Prev 2007;16:2213-7.
69. Currie CJ, Poole CD, Gale EAM. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009, epub ahead of print: 1-12.
70. Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009, epub ahead of print: 1-13.
71. Stattin P, Soderberg S, Hallmans G, et al. Leptin is associated with increased prostate cancer risk. A nested case-referent study. J Clin Endocrinol Metab 2001;86:1341-5.
72. Stattin P, Kaaks R, Johansson R, et al. Plasma leptin is not associated with prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2003;12:474-5.
73. Baillargeon J, Platz EA, Rose DP, et al. Obesity, adipokines, and prostate cancer in a prospective population-based study. Cancer Epidemiol Biomarkers Prev 2006;15:1331-5.
74. Hursting SD, Nunez NP, Varticovski L, Vinson C. The obesity-cancer link: lessons learned froma fatlessmouse. Cancer Res 2007;67:2391-3.
75. Nunez NP, Oh WJ, Rozenberg J, et al. Accelerated tumor formation in a fatless mouse with type 2 diabetes and inflammation. Cancer Res 2006;66:5469-76.